Biologics Market 2020 Top Companies – Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc.
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Biological products include a wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel therapies are emerging for the manufacturing of new biologics which holds a prominent future for biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Biologics are also used in treatment of rare diseases in children like for treatment of Batten disease, cerliponase alfa was approved in 2017 for the first time by U.S. Food and Drug Administration (FDA).
Global Biologics Market: Drivers
The global biologics market is expected to witness significant growth during the forecast period, owing to increasing product launches by key players such as Pfizer, Merck and Co., and GlaxoSmithKline (GSK). For instance, Pfizer has a robust pipeline for vaccines, biosimilars, biologics, and small molecules for 2019. The company has around 100 products in trial phase with 35 in phase 1, 28 in phase 2, 26 in phase 3, and 11 in the process of registration. The most recent one was for Pfizer’s DAURISMO (glasdegib), which received the U.S. Food and Drug Administration (FDA) approval in November 2018. It was indicated for adult patients with newly-diagnosed acute myeloid leukemia for who intensive chemotherapy is not a viable option.
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2663
Moreover, the global biologics market is rapidly growing, owing to increasing number of U.S. FDA approvals for new biologics medicines indicated for the treatment of rare disease. For instance, in December 2017, GlaxoSmithKline (GSK) received the U.S. FDA approval for its biologic ‘Nucala’, which is indicated for the treatment of rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA). Moreover, the U.S. FDA approved around 46 more biologics in 2017.
Global Biologics Market Regional Analysis
Among regions, North America holds dominant position in the global biologics market. This is owing to high presence of major biopharmaceutical and pharmaceutical companies in the U.S. including Biogen Idec, Eli Lily and Compaby, AbbVie, GlaxoSmithKline, Amgen, Novartis, Johnson and Johnson, Sanofi, and Pfizer. Increasing product approvals from regulatory authorities is expected to boost the biologics market in North America. For instance, in 2018, the U.S. FDA’s Center for Drug Evaluation and Research approved 59 novel drugs and biologics and were launched in the U.S.
Furthermore, Asia Pacific is expected to exhibit significant growth in the global biologics market, owing to increasing production of biosimilar products of biologics. A biosimilar is typically a biologic medical product, which is almost an identical copy of the original product that is manufactured by a different company. For instance, Biocon Ltd., an Indian biopharmaceutical company, launched two biosimilars namely CANMAb (trastuzumad) and Krabeva (bevacuzumab) in India in 2017 and 2017. These biosimilars were indicated for the treatment of several types of cancer.
Browse Press Release: https://www.coherentmarketinsights.com/press-release/biologics-market-3010
Global Biologics Market: Competitive Landscape
Key players operating in the global biologics market include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.
Global Biologics Market: Taxonomy
The global biologics market is segmented on the basis of product type, application, end-user, and region.
By Product Type
- Monoclonal Antibodies
- Recombinant Hormones/Proteins
- Cell Therapy
- Gene Therapy
- Infectious Diseases
- Autoimmune Diseases
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- North America
- Latin America
- Asia Pacific
- Middle East
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2663
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire